Sanjay Basu1, Evan Orenstein, Alison P Galvani. 1. Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT 06520, USA. sanjay.basu@yale.edu
Abstract
BACKGROUND: Emerging research suggests that genetically distinct strains of Mycobacterium tuberculosis may modulate the immune system differently. This may be of importance in high-burden settings where > or =1 genetic group of M. tuberculosis confers significant morbidity. METHODS: A dynamic mathematical model was constructed to evaluate how different degrees of cross-immunity among M. tuberculosis groups could affect epidemics of drug-resistant tuberculosis (TB). RESULTS: Simulated populations with immunogenically distinct TB strain groups experienced a heightened risk of drug-resistant TB, compared with populations without such strain diversity, even when the same rates of case detection and treatment success were achieved. The highest risks of infection were observed in populations in which HIV was prevalent. Drug-resistant strains with very low transmission fitness could still propagate in environments with reduced cross-immunity among different strain groups, even after common targets for case detection and treatment success are reached. CONCLUSIONS: It is possible that the propagation of drug-resistant strains could depend not only on the rate of development of resistance and the fitness of the drug-resistant strains but, also, on the diversity of the strains in the region. The risk of infection with drug-resistant strains could be amplified in locations where there is reduced cross-immunity between originating strain groups. This amplification may be most profound during the first few decades of TB treatment expansion.
BACKGROUND: Emerging research suggests that genetically distinct strains of Mycobacterium tuberculosis may modulate the immune system differently. This may be of importance in high-burden settings where > or =1 genetic group of M. tuberculosis confers significant morbidity. METHODS: A dynamic mathematical model was constructed to evaluate how different degrees of cross-immunity among M. tuberculosis groups could affect epidemics of drug-resistant tuberculosis (TB). RESULTS: Simulated populations with immunogenically distinct TB strain groups experienced a heightened risk of drug-resistant TB, compared with populations without such strain diversity, even when the same rates of case detection and treatment success were achieved. The highest risks of infection were observed in populations in which HIV was prevalent. Drug-resistant strains with very low transmission fitness could still propagate in environments with reduced cross-immunity among different strain groups, even after common targets for case detection and treatment success are reached. CONCLUSIONS: It is possible that the propagation of drug-resistant strains could depend not only on the rate of development of resistance and the fitness of the drug-resistant strains but, also, on the diversity of the strains in the region. The risk of infection with drug-resistant strains could be amplified in locations where there is reduced cross-immunity between originating strain groups. This amplification may be most profound during the first few decades of TB treatment expansion.
Authors: Jason R Andrews; Farzad Noubary; Rochelle P Walensky; Rodrigo Cerda; Elena Losina; C Robert Horsburgh Journal: Clin Infect Dis Date: 2012-01-19 Impact factor: 9.079
Authors: Nicholas D Walter; Michael Strong; Robert Belknap; Diane J Ordway; Charles L Daley; Edward D Chan Journal: Respirology Date: 2012-07 Impact factor: 6.424
Authors: Ted Cohen; Paul D van Helden; Douglas Wilson; Caroline Colijn; Megan M McLaughlin; Ibrahim Abubakar; Robin M Warren Journal: Clin Microbiol Rev Date: 2012-10 Impact factor: 26.132
Authors: Shaobin Shang; Sara Gibbs; Marcela Henao-Tamayo; Crystal A Shanley; Gerald McDonnell; Rafael Silva Duarte; Diane J Ordway; Mary Jackson Journal: PLoS One Date: 2011-09-12 Impact factor: 3.240
Authors: R M G J Houben; D W Dowdy; A Vassall; T Cohen; M P Nicol; R M Granich; J E Shea; P Eckhoff; C Dye; M E Kimerling; R G White Journal: Int J Tuberc Lung Dis Date: 2014-05 Impact factor: 2.373
Authors: Sourya Shrestha; Gwenan M Knight; Mariam Fofana; Ted Cohen; Richard G White; Frank Cobelens; David W Dowdy Journal: Open Forum Infect Dis Date: 2014-08-30 Impact factor: 3.835
Authors: Anna Maria Niewiadomska; Bamini Jayabalasingham; Jessica C Seidman; Lander Willem; Bryan Grenfell; David Spiro; Cecile Viboud Journal: BMC Med Date: 2019-04-24 Impact factor: 8.775
Authors: Sourya Shrestha; Emily A Kendall; Rebekah Chang; Roy Joseph; Parastu Kasaie; Laura Gillini; Anthony Todd Fojo; Michael Campbell; Nimalan Arinaminpathy; David W Dowdy Journal: BMC Med Date: 2021-10-14 Impact factor: 11.150